|
KMID : 0378019830260030123
|
|
New Medical Journal
1983 Volume.26 No. 3 p.123 ~ p.129
|
|
|
Clinical Effect of Clobestasol Propionate-Neomycin-Nystatin (Dermovate-NN^(®)) on Psoriasis Eczematous Dermatoses and Intertrigo.
|
|
|
|
|
Abstract
|
|
|
The Dermovate-NN® is a new topical agent containing clobestasol propionate, neomycin and nystatin.
The clobestasol propionate, discovered at 1973, is the variant form of betamethasonevalerate, and introduced as a highly effective corticosteroid especially to psoriasis. Neomycin, a broad spectrum-antibiotic, was widely used with corticosteroids.in eczematous dermatoses.
And nystatin has antifungal effect, especially to candida albicans infection of the skin, mucosa and gastrointestinal tract.
In many instances, ermatologists want to use corticostroids combined with antibiotic and antifungal agent when they meet the patient with psoriasis, eczematous dermatoses or intertrigo.
We have done the clinical trial to evaluate the Dermovate-NN®.
Twenty eight cases of psoriasis, 15 cases of eczematous dermatoses and 30 cases of intertrigo were involved in this trial.
The results were as followings;
1. In psoriasis, 92. 9% of the patients responded to the topical agent during the first 3 weeks (14.3% cured, 25% excellent, 35. 7% good & 17.8% fair) and 7. 1% of the patients showed no response to the therapy.
2. In eczematous dermatoses, all of the patients responded well to the therapy during the first 3 weeks (46.7%) cured, 33.3% excellent & 20% good).
3. In intertrigo, 70% of the patients responded well to the therapy during the first 2 weeks (40% cured, 26.7% excellent & 3.3% good).
For the other 30% of the patients with candidal super infection, the topical agent must be changed to antifungal ointment after one week because of continuous presence of pseudohyphae and blastospores on the 10% KOH preparations.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|